# Anthony W. Tolcher

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/anthony-w-tolcher/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24,458 |
| Field | PI3K/AKT/mTOR signaling in cancer |
| h-index | 76 |
| i10-index | 269 |
| Last Known Institution | Texas Oncology |
| OpenAlex ID | https://openalex.org/A5060992997 |
| ORCID iD | https://orcid.org/0000-0002-6322-9721 |
| Works | 947 |

## Researcher papers

- [Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors](https://scholariq.org/papers/efficacy-and-safety-of-abemaciclib-an-inhibitor-of-cdk4-and-cdk6-for-patients/)
- [Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors](https://scholariq.org/papers/phase-i-study-of-ro4929097-a-gamma-secretase-inhibitor-of-notch-signaling-in/)
- [First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas](https://scholariq.org/papers/first-in-human-phase-i-study-of-copanlisib-bay-80-6946-an-intravenous-pan-class/)
- [Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities](https://scholariq.org/papers/genome-and-transcriptome-sequencing-in-prospective-metastatic-triple-negative/)
- [First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors](https://scholariq.org/papers/first-in-human-study-of-amg-820-a-monoclonal-anti-colony-stimulating-factor-1/)
- [First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01](https://scholariq.org/papers/first-in-human-phase-i-dose-escalation-and-dose-expansion-study-of-trophoblast/)
- [Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study](https://scholariq.org/papers/datopotamab-deruxtecan-in-advanced-or-metastatic-hr-her2-and-triple-negative/)

## Researcher topics

- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [Texas Oncology](https://scholariq.org/institutions/texas-oncology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.